Cerebral aspergillosis;Les aspergilloses cérébrales

Revue Neurologique

Volumn 160, Issue 5 I, 2004, Pages 597-605

  Tattevin, P ^a   Jaureguiberry S ^a   Gangneux, J P ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Bone marrow allograft; Brain abscesses; Immunodepression; Invasive aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGRAFT; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; BRAIN ABSCESS; DIAGNOSTIC VALUE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PROGNOSIS; REVIEW; SURVIVAL;

EID: 2942748501     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)70997-2     Document Type: Review

References (44)

1. ANAES. (2001). Conférence de Consensus: prévention du risque aspergillaire chez les patients immunodéprimés (hématologie, transplantation). Bull Cancer, 88: 589-600.
2. ASCIOGLU S, DE PAUW BE, MEIS JF. (2000). Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents, 15: 159-168.
3. ASCIOGLU S, REX JH, DE PAUW B et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 34: 7-14.
4. BOES B, BASHIR R, BOES C, HAHN F, MCCONNELL JR, MCCOMB R. (1994). Central nervous system aspergillosis. Analysis of 26 patients. J Neuroimaging, 4: 123-129.
5. BOUAKLINE A, LACROIX C, ROUX N, GANGNEUX JP, DEROUIN F. (2000). Fungal contamination of food in hematology units. J Clin Microbiol, 38: 4272-4273.
6. BOWDEN R, CHANDRASEKAR P, WHITE MH et al. (2002). A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis, 35: 359-366.
7. CORNET M, FLEURY L, MASLO C, BERNARD JF, BRUCKER G. (2002). Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect, 51: 288-296.
8. CUCCIA V, GALARZA M, MONGES J. (2000). Cerebral aspergillosis in children. Report of three cases. Pediatr Neurosurg, 33: 43-48.
9. DARRAS-JOLY C, VEBER B, BEDOS JP, GACHOT B, REGNIER B, WOLFF M. (1996). Nosocomial cerebral aspergillosis: a report of 3 cases. Scand J Infect Dis, 28: 317-319.
10. DELONE DR, GOLDSTEIN RA, PETERMANN G, SALAMAT MS, MILES JM, KNECHTLE SJ, BROWN WD. (1999). Disseminated aspergillosis involving the brain: distribution and imaging characteristics. AJNR Am J Neuroradiol, 20: 1597-1604.
11. DENNING DW. (1996). Therapeutic outcome in invasive aspergillosis. Clin Infect Dis, 23: 608-615.
12. DENNING DW. (1998). Invasive aspergillosis. Clin Infect Dis, 26: 781-803; quiz 804-785.
13. DENNING DW. (2002a). Aspergillus species. In: Dolin R, editor. Dolin Rs. Principles and Practice of Infectious Diseases. Philadelphia, USA: Churchill Livingstone. p 2674-2685.
14. DENNING DW. (2002b). Echinocandins: a new class of antifungal. J Antimicrob Chemother, 49: 889-891.
15. DENNING DW, LEE JY, HOSTETLER JS et al. (1994). NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med, 97: 135-144.
16. DENNING DW, RIBAUD P, MILPIED N et al. (2002). Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis, 34: 563-571.
17. DIETRICH U, HETTMANN M, MASCHKE M, DOERFLER A, SCHWECHHEIMER K, FORSTING M. (2001). Cerebral aspergillosis: comparison of radiological and neuropathologic findings in patients with bone marrow transplantation. Eur Radiol, 11: 1242-1249.
18. GANGNEUX JP, BRETAGNE S, CORDONNIER C et al. (2002a). Prevention of nosocomial fungal infection: the French approach. Clin Infect Dis, 35: 343-346.
19. GANGNEUX JP, LAVARDE D, BRETAGNE S, GUIGUEN C, GANDEMER V. (2002b). Transient aspergillus antigenaemia: think of milk. Lancet, 359: 1251.
20. GAUBITZ M, MOSKOPP D, FEGELER W, HILKER E, DOMSCHKE W. (2000). Cerebral aspergillosis in systemic lupus erythematosus. J Rheumatol, 27: 2518-2519.
21. GHANNOUM MA, KUHN DM. (2002). Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res, 7: 242-256.
22. GROLL AH, SHAH PM, MENTZEL C, SCHNEIDER M, JUST-NUEBLING G, HUEBNER K. (1996). Trends in the post mortem epidemiology of invasive fungal infections at a university hospital. J Infect, 33: 23-32.
23. GUERMAZI A, GLUCKMAN E, TABTI B, MIAUX Y. (2003). Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol, 13: 377-388.
24. HAGENSEE ME, BAUWENS JE, KJOS B, BOWDEN RA. (1994). Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis, 19: 402-408.
25. HERBRECHT R, DENNING DW, PATRERSON TF et al. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347: 408-415.
26. KEATING GM, JARVIS B. (2001). Caspofungin. Drugs, 61:1121-1129; discussion 1130-1121.
27. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF. (2002). Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother, 46: 2564-2568.
28. KLEINSCHMIDT-DEMASTERS BK. (2002). Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol, 33: 116-124.
29. LIN SJ, SCHRANZ J, TEUTSCH SM. (2001). Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis, 32: 358-366.
30. LUTSAR I, ROFFEY S, TROKE P. (2003). Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis, 37: 728-732.
31. MACHETTI M, ZOTTI M, VERONI L et al. (2000). Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis, 2: 140-144.
32. MASCHKE M, DIETRICH U, PRUMBAUM M, KASTRUP O, TUROWSKI B, SCHAEFER UW, DIENER HC. (1999). Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant, 23: 1167-1176.
33. MURTHY JM, SUNDARAM C, PRASAD VS, PUROHIT AK, RAMMURTI S, LAXMI V. (2000). Aspergillosis of central nervous system: a study of 21 patients seen in a university hospital in south India. J Assoc Physicians India, 48: 677-681.
34. MYLONAKIS E, PALIOU M, SAX PE, SKOLNIK PR, BARON MJ, RICH JD. (2000). Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore), 79: 269-280.
35. NG TT, DENNING DW. (1995). Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med, 155: 1093-1098.
36. PATTERSON TF. (2002). New azole antifungals. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA.
37. PATTERSON TF, KIRKPATRICK WR, WHITE M et al. (2000). Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore), 79: 250-260.
38. RIBAUD P, CHASTANG C, LATGE JP et al. (1999). Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis, 28: 322-330.
39. SCHWARTZ S, MILATOVIC D, THIEL E. (1997). Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol, 97: 663-665.
40. WALSH TJ, HIER DB, CAPLAN LR. (1985). Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol, 18: 574-582.
41. WALSH TJ, LUTSAR I, DRISCOLL T et al. (2002). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J, 21: 240-248.
42. WHITE MH, ANAISSIE EJ, KUSNE S et al. (1997). Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis, 24: 635-642.
43. YAMADA K, SHRIER DA, RUBIO A et al. (2002). Imaging findings in intracranial aspergillosis. Acad Radiol, 9: 163-171.
44. YOUNG RC, BENNETT JE, VOGEL CL, CARBONE PP, DEVITA VT. (1970). Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore), 49: 147-173.